In the quiet moments of cycling to the office, chopping vegetables for dinner, or folding a week's worth of laundry, my mind is rarely idle. These are the pockets of time when podcasts and audiobooks weave their way into my life. Played at double speed, they transform the

A few months ago, I hit a wall—hard. I’d spent years working with biopharma companies, startups, and investors, trying to help them navigate the labyrinth of European funding and regulation. But over time, I realized something unsettling: being good wasn’t enough. No matter how many introductions I

“Chance favors only the prepared mind,” observed Louis Pasteur, capturing an enduring truth about navigating an unpredictable world. At first glance, this insight champions planning and foresight, yet its deeper resonance lies in the interplay between preparation and action. Pasteur’s wisdom reminds us that readiness isn’t about knowing

Annoyance is humanity’s most underappreciated emotion. It’s a prickly, uncomfortable feeling that demands attention—your brain’s way of saying, “This could be better.” While some dismiss it as unproductive grumbling, annoyance, when properly wielded, becomes a razor-sharp tool for improvement. My own annoyance with atrocious pitch

Total Addressable Market (TAM) is a ubiquitous metric in biotech investment pitches, used to quantify the theoretical revenue potential of novel therapies. Its simplicity and apparent rigor make it an appealing tool for startups seeking to attract investors. At its core, TAM promises a snapshot of market opportunity, assuming full

Biotech investing is not for the faint-hearted. This field, ruled by unpredictability, is a theatre of sharp turns: clinical trials that vault or vaporize fortunes, regulatory whims that recast the rules, and groundbreaking science that reshapes entire markets. Investors, yearning for clarity in the chaos, often cling to deceptively

Hi, I’m Sebastian, and this blog is both an indulgence and an exploration. It’s not for any one person, and yet, perhaps, for everyone. Over the past decade, I’ve worked across nearly every facet of the pharmaceutical industry, helping companies connect through Slate Mountains Capital and the